Macron to unveil Novo Nordisk pharma investment in France

French President Emmanuel Macron will on Thursday inaugurate a "major investment" by Danish pharmaceutical company Novo Nordisk in France, his office said on Wednesday, pitching it as a sign of newly restored French industrial competitiveness.

The investment, for which no detail was provided by Macron's office, will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people. Novo, known for its hugely popular anti-obesity drug Wegovy, produces insulin in France.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)